Literature DB >> 30706354

The impact of national viral hepatitis therapy program and hepatitis B vaccination program on mortality from acute and chronic viral hepatitis in Taiwan.

Shih-Yung Su1.   

Abstract

BACKGROUND: In Taiwan, the national hepatitis B virus vaccination program and national viral hepatitis therapy program were implemented to control the infections of hepatitis viruses and their progressive illnesses. Studies have evaluated the impacts of two national health programs on many liver-related diseases, but not on acute and chronic viral hepatitis. The purpose of this study was to evaluate the impact on the mortality of acute and chronic viral hepatitis.
METHODS: Poisson regression models were used to estimate the adjusted rate ratios of the different period groups and corresponding 95% confidence intervals for childhood, adulthood and elderhood, and to estimate the adjusted rate ratios of vaccinated cohorts and corresponding 95% confidence intervals.
RESULTS: Compared with period of 2000-2003, the adjusted rate ratios for period groups of 2008-2011 and 2012-2015 reported a significantly increasing risk of acute and chronic viral hepatitis mortality, except for the childhood and female adulthood. For population without vaccination, the adjusted rate ratios of acute and chronic viral hepatitis B mortality were 0.99 (95% CIs 0.88-1.12), 1.30 (95% CIs 1.17-1.45) and 1.42 (95% CIs 1.28-1.55) for periods of 2004-2007, 2008-2011 and 2012-2015, respectively, comparing with unimplemented period of national viral hepatitis therapy program. Compared with 1967-1983 cohorts, the adjusted rate ratio of 1984-2000 cohorts was 0.46 (95% CIs 0.28-0.75), and the adjusted rate ratios were 0.49 (95% CIs 0.28-0.87) and 0.35 (95% CIs 0.11-1.05) for male and female, respectively.
CONCLUSION: This study revealed the significantly higher mortality rates of acute and chronic viral hepatitis during the implemented period of national viral hepatitis therapy program, comparing the unimplemented period. Such ineffectiveness may be attributable to the low coverage rate. The national vaccination program was currently an effective strategy for controlling the mortality of viral hepatitis.

Entities:  

Keywords:  Acute and chronic viral hepatitis; Hepatitis B vaccination; Mortality

Mesh:

Substances:

Year:  2019        PMID: 30706354     DOI: 10.1007/s12072-019-09931-w

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  25 in total

1.  Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B.

Authors:  Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Karen Kar-Lum Yiu; Angel Mei-Ling Chim; Shirley Ho-Ting Chu; Hoi-Yun Chan; Joseph Jao-Yiu Sung; Henry Lik-Yuen Chan
Journal:  J Hepatol       Date:  2010-09-07       Impact factor: 25.083

2.  Elderly and long-term care trends and policy in Taiwan: challenges and opportunities for health care professionals.

Authors:  Hsiu-Hung Wang; Shwn-Feng Tsay
Journal:  Kaohsiung J Med Sci       Date:  2012-07-06       Impact factor: 2.744

3.  Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan.

Authors:  Wei-Ju Su; Cheng-Chung Liu; Ding-Ping Liu; Shu-Fong Chen; Ji-Jia Huang; Ta-Chien Chan; Mei-Hwei Chang
Journal:  J Infect Dis       Date:  2012-01-19       Impact factor: 5.226

4.  Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma.

Authors:  Chuen-Fei Chen; Wen-Chung Lee; Hwai-I Yang; Hung-Chuen Chang; Chin-Lan Jen; Uchenna H Iloeje; Jun Su; Chuhsing K Hsiao; Li-Yu Wang; San-Lin You; Sheng-Nan Lu; Chien-Jen Chen
Journal:  Gastroenterology       Date:  2011-06-22       Impact factor: 22.682

Review 5.  Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched.

Authors:  Yin-Chu Chien; Chyi-Feng Jan; Hsu-Sung Kuo; Chien-Jen Chen
Journal:  Epidemiol Rev       Date:  2006-06-16       Impact factor: 6.222

6.  Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study.

Authors:  Mei-Hsuan Lee; Hwai-I Yang; Sheng-Nan Lu; Chin-Lan Jen; Shiou-Hwei Yeh; Chun-Jen Liu; Pei-Jer Chen; San-Lin You; Li-Yu Wang; Wei J Chen; Chien-Jen Chen
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

Review 7.  Towards the eradication of hepatitis B in Taiwan.

Authors:  Suzanne Wait; Ding-Shinn Chen
Journal:  Kaohsiung J Med Sci       Date:  2011-12-16       Impact factor: 2.744

Review 8.  Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?

Authors:  Hans L Tillmann; Kalliopi Zachou; George N Dalekos
Journal:  Liver Int       Date:  2011-11-15       Impact factor: 5.828

9.  Hepatocellular carcinoma in Taiwan.

Authors:  Ding-Shinn Chen
Journal:  Hepatol Res       Date:  2007-09       Impact factor: 4.288

Review 10.  The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysis.

Authors:  Weiyan Yu; Caiyan Zhao; Chuan Shen; Yadong Wang; Hongzhi Lu; Jing Fan
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

View more
  2 in total

1.  Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study.

Authors:  Sufang Wei; Meixin Hu; Hongjie Chen; Qiuli Xie; Peng Wang; Hong Li; Jie Peng
Journal:  BMC Gastroenterol       Date:  2022-08-17       Impact factor: 2.847

2.  Mortality trends in chronic liver disease and cirrhosis from 1981 to 2015 in Taiwan.

Authors:  Shih-Yung Su; Long-Teng Lee; Wen-Chung Lee
Journal:  Popul Health Metr       Date:  2021-10-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.